Chemical Namesotorasib
Dosage FormTablet (oral; 120 mg)
Drug ClassInhibitors
Approval Year2021


  • For the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Lumakras (sotorasib) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA
Document TitleYearSource
Sotorasib for lung cancers with KRAS p.G12C mutation.2021The New England Journal of Medicine